Reuters logo
BRIEF-Astellas announces FDA fast track designation for its DNA vaccine
December 20, 2016 / 1:14 PM / a year ago

BRIEF-Astellas announces FDA fast track designation for its DNA vaccine

Dec 20 (Reuters) - Astellas Pharma Inc :

* Astellas Pharma - phase I clinical trial to evaluate safety, tolerability, immune response of ASP0892 in adults allergic to peanuts has been initiated

* Astellas announces FDA fast track designation for ASP0892, DNA vaccine for mitigation of severe hypersensitivity reactions due to peanut allergy Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below